Business OpportunitiesAurobindo gets USFDA nod for two new drugs
Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received final approval for Zidovudine tablets in 60mg strength and tentative approval for Lamivudine tablets in 30mg – indicated for the treatment of HIV-I infection in combination with other anti-retrovirals (ARVs) – from the US Food and Drug Administration (USFDA).
- Aurobindo Pharma gets USFDA approval for CVS drug - Aurobindo sues S African govt over AIDS drug contract - Aurobindo Pharma gets TGA Australia nod for nerve drug - Aurobindo Phrama gets USFDA nod for veterinary drug - Aurobindo expands pact with Pfizer - Aurobindo expands licensing pact with Pfizer, adds 60 drugs
Both the new drug applications are for paediatric strengths and are developed based on the United Nations’ initiative to develop paediatric formulations. With this, Aurobindo now has a total of 98 abbreviated new drug application (ANDA) approvals (70 final and 28 tentative) from the USFDA, which include 30 products in the ARV segment, the company said in a filing to the BSE on Friday.
The scrip of Aurobindo is currently trading at Rs 546 on the BSE, up 0.02 per cent as against the previous close of Rs 545.90.